These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31287620)

  • 1. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis.
    Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Wilson D; Jani I; Apollo T; Sculpher M; Hallett T; Kerr C; van Oosterhout JJ; Eaton JW; Estill J; Williams B; Doi N; Cowan F; Keiser O; Ford D; Hatzold K; Barnabas R; Ayles H; Meyer-Rath G; Nelson L; Johnson C; Baggaley R; Fakoya A; Jahn A; Revill P
    J Int AIDS Soc; 2019 Jul; 22(7):e25325. PubMed ID: 31287620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis.
    Cambiano V; Johnson CC; Hatzold K; Terris-Prestholt F; Maheswaran H; Thirumurthy H; Figueroa C; Cowan FM; Sibanda EL; Ncube G; Revill P; Baggaley RC; Corbett EL; Phillips A;
    J Int AIDS Soc; 2019 Mar; 22 Suppl 1(Suppl Suppl 1):e25243. PubMed ID: 30907498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis.
    Dunning L; Gandhi AR; Penazzato M; Soeteman DI; Revill P; Frank S; Phillips A; Dugdale C; Abrams E; Weinstein MC; Newell ML; Collins IJ; Doherty M; Vojnov L; Fassinou Ekouévi P; Myer L; Mushavi A; Freedberg KA; Ciaranello AL
    J Int AIDS Soc; 2021 Jan; 24(1):e25651. PubMed ID: 33474817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing HIV retesting during pregnancy and postpartum in four countries: a cost-effectiveness analysis.
    Meisner J; Roberts DA; Rodriguez P; Sharma M; Newman Owiredu M; Gomez B; de Mello MB; Bobrik A; Vodianyk A; Storey A; Githuka G; Chidarikire T; Barnabas R; Farid S; Essajee S; Jamil MS; Baggaley R; Johnson C; Drake AL
    J Int AIDS Soc; 2021 Apr; 24(4):e25686. PubMed ID: 33787064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.
    Phillips A; Cambiano V; Nakagawa F; Mabugu T; Miners A; Ford D; Pillay D; De Luca A; Lundgren J; Revill P
    PLoS One; 2014; 9(10):e109148. PubMed ID: 25290340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.
    Bassett IV; Govindasamy D; Erlwanger AS; Hyle EP; Kranzer K; van Schaik N; Noubary F; Paltiel AD; Wood R; Walensky RP; Losina E; Bekker LG; Freedberg KA
    PLoS One; 2014; 9(1):e85197. PubMed ID: 24465503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study.
    Rodriguez PJ; Roberts DA; Meisner J; Sharma M; Owiredu MN; Gomez B; Mello MB; Bobrik A; Vodianyk A; Storey A; Githuka G; Chidarikire T; Barnabas R; Barr-Dichiara M; Jamil MS; Baggaley R; Johnson C; Taylor MM; Drake AL
    Lancet Glob Health; 2021 Jan; 9(1):e61-e71. PubMed ID: 33227254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.
    Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ
    Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.